Illumina Boosts Full-Year Guidance on Strong Q2 Performance
Event summary
- Illumina reported Q2 2026 revenue of $1.16 billion, up 9.5% YoY and 8.1% organically (excluding currency, acquisitions, and China).
- GAAP operating margin was 21.1%, with non-GAAP diluted EPS at $1.31.
- Full-year revenue guidance raised to $4.60-$4.64 billion from prior $4.52-$4.62 billion.
- Free cash flow for Q2 was $162 million, down from $204 million in the prior year period.
The big picture
Illumina's strong Q2 performance reflects growing adoption of sequencing-intensive applications in clinical settings. The company is expanding its workflow and multiomics capabilities, broadening the value of its ecosystem. However, integration challenges from recent acquisitions and regulatory risks in China remain key strategic considerations.
What we're watching
- Product Demand
- How sustained demand for NovaSeq X will impact Illumina's top-line growth.
- Integration Challenges
- Whether Illumina can successfully integrate SomaLogic and other acquisitions into its operations.
- Regulatory Risks
- The pace at which China's 'unreliable entities list' designation may affect Illumina's business.
Related topics